(Q45872630)

17 December 2017

title

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). (English)

1 reference

17 December 2017

main subject

hemophilia

0 references

Coagulation factor VIII

0 references

coagulation factor IX

0 references

author name string

Hay CR

1

1 reference

17 December 2017

Baglin TP

2

1 reference

17 December 2017

Collins PW

3

1 reference

17 December 2017

Hill FG

4

1 reference

17 December 2017

Keeling DM

5

1 reference

17 December 2017

language of work or name

English

0 references

publication date

1 October 2000

1 reference

17 December 2017

British Journal of Haematology

published in

1 reference

17 December 2017

volume

111

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

78-90

1 reference

17 December 2017

Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Immune tolerance and the immune modulation protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Platelet activation induced by porcine factor VIII (Hyate:C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

In vitro detection of mild inhibitors to factor VIII in hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Comparison of anti-human and anti-porcine factor VIII inhibitor levels in 63 patients with severe haemophilia A. A French Multicentric Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Continuous infusion of monoclonal antibody-purified factor VIII: rational approach to serious hemorrhage in patients with allo-/autoantibodies to factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

DDAVP in acquired hemophilia A: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Comparative study of four different pharmacokinetic computer programs: case study of a factor VIII preparation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Cyclosporin treatment of a woman with acquired haemophilia due to factor VIII:C inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Acquired haemophilia and rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Acquired haemophilia and rheumatoid arthritis: success of immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

GUIDELINES ON THERAPEUTIC PRODUCTS TO TREAT HAEMOPHILIA AND OTHER HEREDITARY COAGULATION DISORDERS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

Management of haemophilia B patients with inhibitors and anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02327.X

10.1046/J.1365-2141.2000.02327.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017